Cargando…

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma

SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholan...

Descripción completa

Detalles Bibliográficos
Autores principales: Auer, Timo Alexander, Collettini, Federico, Segger, Laura, Pelzer, Uwe, Mohr, Raphael, Krenzien, Felix, Gebauer, Bernhard, Geisel, Dominik, Hosse, Clarissa, Schöning, Wenzel, Fehrenbach, Uli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177209/
https://www.ncbi.nlm.nih.gov/pubmed/37174120
http://dx.doi.org/10.3390/cancers15092655
_version_ 1785040584139866112
author Auer, Timo Alexander
Collettini, Federico
Segger, Laura
Pelzer, Uwe
Mohr, Raphael
Krenzien, Felix
Gebauer, Bernhard
Geisel, Dominik
Hosse, Clarissa
Schöning, Wenzel
Fehrenbach, Uli
author_facet Auer, Timo Alexander
Collettini, Federico
Segger, Laura
Pelzer, Uwe
Mohr, Raphael
Krenzien, Felix
Gebauer, Bernhard
Geisel, Dominik
Hosse, Clarissa
Schöning, Wenzel
Fehrenbach, Uli
author_sort Auer, Timo Alexander
collection PubMed
description SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinoma (iCCA). Due to the rarity of cHCC-CCA, no interventional therapies have been established. This review provides an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. ABSTRACT: cHCC-CCA is an uncommon type of liver cancer that exhibits clinical and pathological characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), which are the two main forms of primary liver cancer. The similarity to HCC and CCA makes therapeutical strategies challenging. The poor prognosis of CCA in general, as well as for cHCC-CCA, is mainly attributable to the fact that diagnosis is often at an advanced stage of disease. During the last decade, locoregional therapies usually performed by interventional radiologists and its established role in HCC treatment have gained an increasing role in CCA treatment as well. These comprise a wide range of options from tumor ablation procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), computed tomography high-dose rate brachytherapy (CT-HDRBT), and cryoablation to transarterial chemoembolization (TACE), including the option of intra-arterial administration of radioactive spheres (transarterial radioembolization—TARE), and much attention has focused on the potential of individual concepts in recent years. The purpose of this review is to provide an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future.
format Online
Article
Text
id pubmed-10177209
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101772092023-05-13 Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma Auer, Timo Alexander Collettini, Federico Segger, Laura Pelzer, Uwe Mohr, Raphael Krenzien, Felix Gebauer, Bernhard Geisel, Dominik Hosse, Clarissa Schöning, Wenzel Fehrenbach, Uli Cancers (Basel) Review SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare form of liver cancer with features of both hepatocellular and biliary tract cancer. Locoregional tumor therapies are an integral part of the treatment strategies of hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinoma (iCCA). Due to the rarity of cHCC-CCA, no interventional therapies have been established. This review provides an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. ABSTRACT: cHCC-CCA is an uncommon type of liver cancer that exhibits clinical and pathological characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), which are the two main forms of primary liver cancer. The similarity to HCC and CCA makes therapeutical strategies challenging. The poor prognosis of CCA in general, as well as for cHCC-CCA, is mainly attributable to the fact that diagnosis is often at an advanced stage of disease. During the last decade, locoregional therapies usually performed by interventional radiologists and its established role in HCC treatment have gained an increasing role in CCA treatment as well. These comprise a wide range of options from tumor ablation procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), computed tomography high-dose rate brachytherapy (CT-HDRBT), and cryoablation to transarterial chemoembolization (TACE), including the option of intra-arterial administration of radioactive spheres (transarterial radioembolization—TARE), and much attention has focused on the potential of individual concepts in recent years. The purpose of this review is to provide an overview of current radiologic interventions for CCA (excluding options for eCCA), to review and appraise the existing literature on the topic, and to provide an outlook on whether such interventions may have a role as treatment for cHCC-CCA in the future. MDPI 2023-05-08 /pmc/articles/PMC10177209/ /pubmed/37174120 http://dx.doi.org/10.3390/cancers15092655 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Auer, Timo Alexander
Collettini, Federico
Segger, Laura
Pelzer, Uwe
Mohr, Raphael
Krenzien, Felix
Gebauer, Bernhard
Geisel, Dominik
Hosse, Clarissa
Schöning, Wenzel
Fehrenbach, Uli
Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
title Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
title_full Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
title_fullStr Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
title_full_unstemmed Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
title_short Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
title_sort interventional treatment strategies in intrahepatic cholangiocarcinoma and perspectives for combined hepatocellular-cholangiocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177209/
https://www.ncbi.nlm.nih.gov/pubmed/37174120
http://dx.doi.org/10.3390/cancers15092655
work_keys_str_mv AT auertimoalexander interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT collettinifederico interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT seggerlaura interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT pelzeruwe interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT mohrraphael interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT krenzienfelix interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT gebauerbernhard interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT geiseldominik interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT hosseclarissa interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT schoningwenzel interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma
AT fehrenbachuli interventionaltreatmentstrategiesinintrahepaticcholangiocarcinomaandperspectivesforcombinedhepatocellularcholangiocarcinoma